A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F22%3A10157184" target="_blank" >RIV/00098892:_____/22:10157184 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/22:73614868
Result on the web
<a href="https://www.mdpi.com/1648-9144/58/3/336" target="_blank" >https://www.mdpi.com/1648-9144/58/3/336</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/medicina58030336" target="_blank" >10.3390/medicina58030336</a>
Alternative languages
Result language
angličtina
Original language name
A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma
Original language description
Background and Objectives: Complete pathological response after ipilimumab and nivolumab combination therapy in a patient with intermediate prognosis renal cell carcinoma is an uncommon finding. Case presentation: A 60-year-old man presented with synchronous solitary metastatic bone lesion and renal cell carcinoma and achieved a complete pathological response after surgical resection of the bone lesion, followed by ipilimumab and nivolumab combination therapy and nephrectomy. The treatment was complicated by hypophysitis and oligoarthritis more than a year after the initiation of the therapy. Conclusions: Currently, the combination therapy based on immune checkpoint inhibitors represents the treatment of choice in patients with intermediate- and poor-risk prognosis metastatic renal cell carcinoma. In the present case, preoperative therapy with ipilimumab and nivolumab resulted in a complete pathological response in the renal tumor. Vigilance concerning potential immune-related side effects is warranted throughout the course of therapy and the subsequent follow-up.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Medicina-Lithuania
ISSN
1010-660X
e-ISSN
1648-9144
Volume of the periodical
58
Issue of the periodical within the volume
3
Country of publishing house
CH - SWITZERLAND
Number of pages
10
Pages from-to
336
UT code for WoS article
000774151800001
EID of the result in the Scopus database
2-s2.0-85125383471